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Dear Editor,
The Gram-negative bacillus Burkholderia gladioli is known to be
a causative pathogen of pneumonia in cystic fibrosis [1,2].
Chronic lower respiratory infections involving B. gladioli are
associated with poor graft survival and unfavourable outcomes
[1,2]. Burkholderia gladioli was first identified as a plant
pathogen in gladiolus, iris and rice, but this bacterium is found
in diverse environments including soil, plants and the human
respiratory tract. Its pathogenesis in humans was first
described in the mid-1990s in case reports of cystic fibrosis
[3] and chronic granulomatous disease [4], and the majority of
the reported B. gladioli infections have been in immunocom-
promised adults, e.g. human immunodeficiency virus-infected
patients, and newborns [5]. Although it is still a fairly
uncommon pathogen, B. gladioli in humans is an opportunistic
pathogen and is associated with a poor prognosis.
The genus Burkholderia was formerly classified as the genus
Pseudomonas. The virulence of B. gladioli in humans is recog-
nized to be low, and the clinical manifestations of this pathogen
in non-lung transplantation patients have not been fully
elucidated. We treated a 62-year-old female patient with
myasthenia gravis, a thymoma and immune-mediated granul-
ocytopenia. She had been treated with tacrolimus for the
previous 12 months. From her sputum, non-fermenting
Gram-negative rods were cultured microbiologically. The
isolate was oxidase-negative, indole-negative and nitrate-neg-
ative. The 16S rRNA detection in our collaborator’s labora-
tory confirmed B. gladioli as a 99% comparable DNA sequence.
The patient’s case was complicated with bronchiolitis followed
by bacteraemia due to B. gladioli. The infection of B. gladioli
presented as diffuse panbronchiolitis (Fig. 1) and progressed
into repeated bacteraemia. The pathogen was not isolated
because a laboratory technician made an arbitrary decision not
to proceed further to determine the species of the causative
organism, although the patient had been suffering from
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FIG. 1. Pulmonary infection by Burkholderia gladioli presenting as diffuse panbronchiolitis. (a) Transverse view showing the transbronchial
distribution of small opaque nodules in the right upper lobe (S2), indicated by arrowheads. (b) Nodular infiltration shadows formed a consolidation in
the left lower lobe (S10), indicated in the area surrounded by arrowheads. (c) The coronal image construction shows diffuse distribution of airway
thickness located in multiple lobes, similar to diffuse panbronchiolitis, marked by arrowheads.
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repeated bacteraemia due to the same bacillus. Our institute’s
laboratory reported the pathogen only as ‘an environmental
non-fermenting Gram-negative rod.’
Non-fermenting Gram-negative bacilli are bradytrophic and
can survive for long periods in a wet environment without
sufficient nutrients. Such bacilli include Pseudomonas spp.,
Acinetobacter spp., Stenotrophomonas spp., Chryseobacterium spp.
and Burkholderia spp., all of which are opportunistic pathogens.
Non-fermenting Gram-negative bacilli have the following
microbiological characteristics: (1) they produce various
b-lactamases in nature, (2) they show multidrug resistance in
nature, (3) they easily acquire plasmids harbouring antibi-
otic-resistant genes, and (4) they form a biofilm on surfaces to
colonize. All of these features are linked to clinical issues in the
treatment of infection, and they are linked to unfavourable
outcomes.
As stated in the position paper distributed by the US
Health Care Infection Control Practices Advisory Commit-
tee (HICPAC), the surveillance of newly emerging pathogens
is a critically important component of prudent infection
control. Microbiological identification is also crucial, espe-
cially using samples obtained in clinical settings. In our
patient, the isolated bacterium was not multidrug-resistant,
fortunately; she was treated successfully with a carbapenem
antibiotic, meropenem (0.5 g, three times per day, admin-
istered for 11 days). We recommend the microbiological
identification of non-fermenting Gram-negative bacilli
according to the clinical situation, even when the bacillus
is likely to be found in the environment and is an
unremarkable microbe. To do so, interdisciplinary interac-
tions between clinical and laboratory personnel are helpful.
The value of medical microbiology is based on interactive
laboratories.
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